Abstract: This invention provides methods for the diagnosis of systemic lupus erythematosus in patients, the sera of which contain antibodies reactive against ribosomal proteins P0, P1 and P2. A peptide containing an amino acid sequence corresponding to the carboxyl termini of the ribosomal proteins, which peptide is bound to a solid carrier, is also provided for use in such methods.

Abstract: Novel cannabinol derivatives are provided which can be used in improved immunoassays for the detection in blood or urine samples of cannabinol metabolites.

Abstract: Topical application of glyciphosphoramide for treatment of cancerous ulcerations and tumor conditions are disclosed.

Abstract: A polypeptide having interferon activity which has an amino acid sequence corresponding to an amino acid sequence of an interferon selected from rIFN-.alpha., hybrid rIFN-.alpha., rIFN-.beta. and rIFN-.gamma. interferons in which at least one cysteine residue in the amino acid sequence has been replaced by an amino acid residue which is incapable of forming intermolecular disulfide bonds is provided. There are also provided a dsDNA sequence encoding the novel polypeptide; a replicable plasmidic expression vehicle containing the dsDNA encoding the novel polypeptides of the invention; a microorganism which has been transformed with the replicable plasmidic expression vehicle; and a method of preparing the dsDNA which encodes the novel polypeptides of the invention.

Abstract: The invention is concerned with novel heterocyclic compounds of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as hereinafter set forth, and their acid addition salts, processes for the preparation of these compounds, pest control compositions which contain these compounds as the active substance, as well as the methods of use of such compounds or compositions for the control of pests.

Abstract: The present disclosure relates to synthetic peptides derived from the conserved region of the HTLVIII envelope proteins. These peptides are useful as reagents for immunoassays for detection of AIDS antibodies, as components of immunogenic compositions useful as vaccines, and for the production of anti-bodies selective to said envelope protein and methods for detecting the presence of AIDS antibodies in biological fluid samples.

Abstract: This disclosure relates to the synthesis by application of recombinant DNA technology of recombinant reovirus nonstructural protein sigma NS and its use as a non-specific binding agent for single stranded (ss) RNA's. This property of sigma NS protein can be employed when it is used as a reagent in protecting unstable RNA during extraction processes and more significantly as a reagent for the concentration of (ss) RNA samples for use in hybridization probe assays.

Abstract: The invention is directed to analogs of GRF or fragments thereof wherein the fragment is reduced in number by one to fifteen amino acids from the carboxyl end wherein the analogs have the formula: ##STR1## wherein R is desNH.sub.2 -Tyr, Tyr, D-Tyr, Ac-Tyr, His or C.sup..alpha. -Methyl-Tyr; R.sub.1 is Ala, N-Methyl-D-Ala or D-Ala; R.sub.2 is Lys, Ala, Leu, Val or Ile; R.sub.3 is Ala, Leu, Val, Ile, Nle, Nval, .beta.-Ala or .alpha.-Aib; R.sub.4 is Lys, Ala, Leu, Val or Ile; R.sub.5 is Met, Leu, Nle or Ile; R.sub.6 is Asn or Ser; X is hydrogen or --COR.sub.7 ; R.sub.7 is hydrogen, C.sub.1-4 alkyl or halo(C.sub.1-4)alkyl; Y is --OR.sub.8 or --NR.sub.9 R.sub.10 ; R.sub.8 is hydrogen or C.sub.1-5 -alkyl; R.sub.9 and R.sub.10 independently equal hydrogen, C.sub.1-7 alkyl, C.sub.2-4 alkenyl or halo(C.sub.1-4)alkyl; and pharmaceutically acceptable acid or base addition salts thereof. The invention is further directed to pharmaceutical compositions and to methods for treating growth hormone deficiencies.

Abstract: Novel vasoactive intestinal peptide analogs containing substitutions of appropriately selected amino acids at specific positions of the VIP molecule, with potent sustained bronchodilatory activity without cardiovascular side effects.

Abstract: Adsorbents, which are suitable for the affinity chromatography of proteins, especially of interferons, and which consist of an electroneutral carrier matrix, --O--CH.sub.2 --CH(OH)--CH.sub.2 --NH- groups as the spacer and a triazine coloring substance bonded to the spacer.

Abstract: The invention is directed to fungicidal pyridine derivatives and their N-amino salts and acid addition salts, said pyridine derivatives having the formula ##STR1## wherein R is mono-, di- or trisubstituted phenyl, wherein the substituents are the same or different and are selected from the group consisting of 1 to 3 halogen, 1 or 2 C.sub.1-3 -alkyl, 1 or 2 C.sub.1-3 -alkoxy and 1 or 2 trifluoromethyl moieties; R.sup.1 is hydrogen, C.sub.1-6 -alkyl, C.sub.2-6 -alkenyl or C.sub.2-6 -alkynyl; R.sup.2 is hydrogen; R.sup.3 is selected from the group consisting of --CO--R.sup.4, --C(OR.sup.5).dbd.CHR.sup.6, --CH(R.sup.4)OR.sup.5, --C(R.sup.4).dbd.NOR.sup.7 and ##STR2## R.sup.4 is hydrogen or C.sub.1-5 -alkyl; R.sup.5 is C.sub.1-4 -alkyl; R.sup.6 and R.sup.7 are hydrogen or C.sub.1-4 -alkyl; n is 2 or 3; or R.sup.2 taken together with R.sup.4 is equal to the group --CH.dbd.

Abstract: The effect of a controlled release, hydrodynamically balanced dosage formulation containing both an aqueous phase N-nitroso compound blocking agent and a lipid phase N-nitroso compound blocking agent in preventing the formation of nitrosamines and nitrosamides in the stomach is disclosed.

Abstract: An intact human immune interferon protein and a method for the extraction and purification of intact recombinant human immune interferon is disclosed. This method permits the purification to homogenity of intact recombinant human immune interferon.

Abstract: Disclosed herein are methods and means of microbially preparing novel human hybrid leukocyte interferons, useful in the treatment of viral and neoplastic diseases, by DNA recombination of parental interferon genes, taking advantage of common restriction endonuclease cleavage sites therein and in carrier expression plasmids.

Abstract: The crystallization of human leukocyte interferon is described. In a preferred embodiment crystalline recombinant human leukocyte interferon A (IFL-rA) is prepared.

Abstract: A process is described for the preparation of fat-soluble vitamin active beadlet compositions which exhibit superior stability when exposed to the feed pelleting process. The process includes forming an aqueous emulsion of a fat-soluble vitamin-active material, gelatin, and a sugar converting the emulsion to dry particulate form containing the non-aqueous constituents of the emulsion and heat treating the resulting product to form water insoluble beadlets.

Abstract: A DNA-directed in vitro assay for measuring the formation of the initial NH.sub.2 -terminal dipeptides or tripeptides which are characteristic of a particular gene product is disclosed. This invention also encompasses a kit consisting of the reagents necessary to perform this method so as to measure or identify a product of gene expression.

Abstract: The present invention provides for peptide derivatives, a process for their manufacture and pharmaceutical preparations containing the same. The invention is also concerned with novel intermediates used in the manufacture of said derivatives.

Abstract: A convenient immunoassay for detecting the presence of oligomeric forms of peptides and proteins is described. The assay employs the sandwich technique with a monoclonal antibody selective for a single epitope on the peptide or protein bound to a solid phase and the same monoclonal antibody labeled with a detectable label in the solution phase.

Abstract: An improved photometric method for the determination of inorganic phosphate in fluids is disclosed.The method makes use of two reagents, an acid reagent and an ammonium molybdate reagent. Utilizing these reagents, the method comprises the following steps:(a) forming a first mixture consisting of a sample fluid and acid reagent;(b) measuring the light absorbance of said first mixture;(c) forming a second mixture consisting of said first mixture and ammonium molybdate reagent;(d) measuring the light absorbance of said second mixture;(e) calculating the difference in light absorbance (.DELTA.A sample) between the light absorbances measured for said first and second mixtures; and,(f) determining the concentration of inorganic phosphate in said sample fluid by comparing the difference in light absorbance (.DELTA.A sample) for said sample fluid to the difference in light absorbance (.DELTA.A standard) for a standard fluid having a known concentration of inorganic phosphate, .DELTA.